At three years, 52.4% of high-risk patients who received catheter-based tricuspid valve repair were alive without a heart-failure hospitalization, compared with 21.0% of those treated with medical therapy alone, according to a randomized trial published Sunday in the New England Journal of Medicine. The estimated hazard ratio was 0.40, indicating a 60% relative reduction in the combined risk of death or hospitalization during follow-up.

The German TRIC-I-HF study is the first randomized evaluation of transcatheter tricuspid repair to demonstrate a statistically significant improvement in both survival and heart-failure hospitalization, rather than symptoms or quality of life alone. Investigators presented the results August 30 at the European Society of Cardiology Congress in Munich, where the ESC said the findings could inform future treatment guidelines.

The result matters because severe tricuspid regurgitation has long been treated as the neglected side of valvular heart disease. Patients are often elderly, medically fragile and referred only after chronic venous congestion has damaged the kidneys or liver. The new evidence suggests that repairing the leaking valve can change that trajectory in carefully selected patients, although the unusually experienced centers and advanced disease profile in the trial limit how broadly the numbers should be applied.

Why Tricuspid Regurgitation Becomes Systemic Disease

The tricuspid valve controls blood flow between the right atrium and right ventricle. When its leaflets fail to close, blood moves backward with every heartbeat, raising venous pressure and forcing the right side of the heart to handle excess volume. Patients may develop shortness of breath, profound fatigue, leg swelling, abdominal fluid and progressive enlargement of the right chambers. Unlike a narrowed valve, the problem can worsen gradually while routine symptoms are attributed to age or other heart disease.

Roughly four in five cases are secondary to changes elsewhere in the heart rather than primary damage to the valve itself. Atrial fibrillation can enlarge the valve ring, left-sided heart disease can raise pressure throughout the circulation, and pacemaker or defibrillator leads can interfere with leaflet movement. An ACC review published in June described these overlapping mechanisms and warned that late congestion, including abdominal swelling and abnormal liver function, often signals an advanced stage.

Drug treatment is largely directed at the consequences. Diuretics remove excess fluid and may relieve swelling, but they do not reliably restore leaflet closure or reverse the mechanical leak. Escalating doses can also become difficult when kidney function deteriorates. Open surgery remains appropriate for some patients, especially when performed with another valve operation, but isolated tricuspid surgery has historically carried substantial risk in the older, sicker population most likely to present late.

A Repair Performed Through a Vein

Transcatheter edge-to-edge repair offers a less invasive alternative. A thin delivery system is advanced through a vein into the right side of the heart, where an implant brings portions of the valve leaflets together and reduces the opening through which blood regurgitates. The procedure depends on detailed echocardiographic imaging, favorable valve anatomy and a multidisciplinary heart team able to decide whether repair, full valve replacement, surgery or continued medical care is the best fit.

In TRIC-I-HF, 360 patients at 29 high-volume German valve centers were randomly assigned in a two-to-one ratio: 237 to catheter repair plus medical therapy and 123 to medical therapy alone. Their mean age was 80.3 years, 56.4% were women and three-quarters had New York Heart Association class III or IV symptoms. Enrollment required severe regurgitation plus a marker of high event risk, such as hospitalization during the previous year or evidence of cardiorenal or cardiohepatic syndrome. The registered protocol planned three years of follow-up.

Operators could choose a suitable commercially available repair system, making the experiment a test of treatment strategy rather than one branded implant. Edge-to-edge repair was used in 98.3% of procedures; approximately two-thirds used the Pascal system and one-third used TriClip. That design reflects European practice, where multiple CE-marked systems are available, but it complicates direct translation to countries with different approvals, operator experience and reimbursement rules.

Hard Outcomes Change the Evidence

Earlier randomized studies had established that catheter repair could reduce leakage and improve how patients felt, but they did not initially prove a reduction in death or hospitalization. In the 350-patient TRILUMINATE trial, the treatment improved a hierarchical composite largely through better quality-of-life scores at one year; mortality and heart-failure hospitalization were not significantly different. That evidence supported adoption while leaving open whether the procedure altered disease rather than symptoms.

TRIC-I-HF enrolled a substantially higher-risk group and observed more clinical events. At one year, a hierarchical endpoint combining death, hospitalization and failure to achieve meaningful quality-of-life improvement favored intervention, with a win ratio of 2.42. By three years, estimated survival was 72.3% after repair and 53.9% with medical therapy, while freedom from heart-failure hospitalization was 62.4% and 31.0%, respectively. An independent trial report calculated that four patients would need treatment to prevent one death or heart-failure hospitalization at one year.

The physiological explanation is plausible but remains partly inferential. Reducing backward flow can lower venous congestion, improve forward circulation and make diuretic therapy more effective when kidney and liver dysfunction have begun to reinforce heart failure. At one year, 56.3% of repaired patients had only mild residual regurgitation, compared with 19.2% in the control group. Functional status and Kansas City Cardiomyopathy Questionnaire scores also improved more after intervention, aligning the clinical events with measurable changes in valve performance and patient experience.

Important Limits Behind the Large Effect

The trial was open label, so patients and clinicians knew which treatment had been assigned. Death and hospitalization are less susceptible to expectation than symptom scores, but decisions to admit a patient can still be influenced by care patterns. The unequal two-to-one randomization left a relatively small control group, and 48 control patients crossed over to repair after a qualifying episode of severe heart failure. Crossover can dilute or complicate comparisons, even when statistical methods retain patients in their original groups.

The participating hospitals were also unusually experienced, averaging 176 transcatheter tricuspid procedures before the study. Outcomes at emerging programs may differ because imaging, device positioning and patient selection are technically demanding. The FDA approval for TriClip specifically requires symptomatic severe disease despite optimal medical therapy, elevated surgical risk, suitable anatomy and review by a multidisciplinary heart team. The German trial should not be read as support for treating every severe echocardiographic finding.

Funding and investigator relationships also require proportionate disclosure. The German Center for Cardiovascular Research and Ludwig Maximilian University supported the work, with additional funding from Edwards Lifesciences, whose Pascal device was used in most procedures. Principal investigators reported speaking or consulting relationships with Edwards, and one reported ties to Tricares. Those relationships do not negate randomized outcomes, but independent replication, device-specific analyses and complete adverse-event reporting will be important.

Referral and Guidelines Are the Next Test

For U.S. clinicians, the practical consequence is likely to be earlier referral rather than immediate universal treatment. The FDA has already approved both an edge-to-edge repair system and a transcatheter replacement option for selected high-risk patients. Repair generally has a favorable early safety profile and avoids the pacemaker risk seen with replacement, while replacement may eliminate regurgitation more completely. Anatomy, right-ventricular function, existing device leads, bleeding risk and the ability to tolerate anticoagulation all influence the choice.

The new trial may also shift the evidence used by guideline committees and insurers. Until now, approvals and coverage discussions rested heavily on reduction of regurgitation, functional improvement and quality of life. A randomized survival and hospitalization signal strengthens the case that the intervention can be disease-modifying in an enriched, high-risk population. It also raises a harder economic question: whether health systems can identify eligible patients before organ dysfunction becomes irreversible and deliver the procedure at centers with enough volume to reproduce the trial.

TRIC-I-HF establishes that catheter repair can improve hard outcomes in a defined group of elderly patients with severe tricuspid regurgitation and manifest right-sided heart failure. It does not establish the best device, the optimal timing for less-sick patients or the results expected at lower-volume hospitals. The next phase will depend on subgroup analyses, longer follow-up and real-world registries showing whether the survival and hospitalization benefits persist when the procedure moves beyond expert German centers.